J Korean Soc Magn Reson Med.  2012 Apr;16(1):40-46. 10.13104/jksmrm.2012.16.1.40.

Feasibility of In vivo Proton Magnetic Resonance Spectroscopy for Lung Cancer

• Yoon SH
• Park CM
• Lee CH
• Song IC
• Lee HJ
• Goo JM

• KMID: 2099836
• DOI: http://doi.org/10.13104/jksmrm.2012.16.1.40

Abstract

PURPOSE
To investigate the feasibility of in vivo proton magnetic resonance spectroscopy (MRS) for evaluation of lung cancer.
MATERIALS AND METHODS
This prospective study was approved by the institutional review board of our hospital and informed consent was obtained in all patients. Ten patients (7 men, 3 women; mean age, 64.4) with pathologicallyproven lung cancer (mean, 56.8 mm; range, 44-77 mm) were enrolled to 1.5 T MRS using a single-voxel respiration-triggered point-resolved spectroscopic sequence. Technical success rate and the reason of technical failure, if any, were investigated.
RESULTS
Out of 10 lung cancers, analyzable MRS spectra were obtained in 8 tumors (technical success rate, 80%). Two MRS datasets were not able to be analyzed due to serious baseline distortion. Choline and lipid signals were detected as major metabolites in analyzable MRS spectra.
CONCLUSION
In vivo proton MRS method using a single-voxel respiration-triggered point-resolved spectroscopic sequence is feasible in obtaining the MR spectra of lung cancer because these spectra were analyzable and high success rate was shown in our study although there was the limitation of small patient group.

Keyword

Magnetic resonance; Spectroscopy; Lung cancer

MeSH Terms

Choline
Ethics Committees, Research
Humans
Informed Consent
Lung
Lung Neoplasms
Magnetic Resonance Spectroscopy
Magnetics
Magnets
Male
Prospective Studies
Protons
Spectrum Analysis
Choline
Protons

Reference

1. Brescia FJ. Lung cancer--a philosophical, ethical, and personal perspective. Crit Rev Oncol Hematol. 2001. 40:139–148.

2. Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. The New England Journal of Medicine. 2005. 352:2714–2720.

3. Golder W. Magnetic resonance spectroscopy in clinical oncology. Onkologie. 2004. 27:304–309.

4. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med. 2003. 49:223–232.

5. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology. 1999. 213:473–480.

6. Yeung DKW, Cheung HS, Tse GMK. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy-Initial results. Radiology. 2001. 220:40–46.

7. Allen JR, Prost RW, Griffith OW, Erickson SJ, Erickson BA. In vivo proton (H1) magnetic resonance spectroscopy for cervical carcinoma. Am J Clin Oncol. 2001. 24:522–529.

8. Hanaoka H, Yoshioka Y, Ito I, Niitu K, Yasuda N. In vitro characterization of lung cancers by the use of 1H nuclear magnetic resonance spectroscopy of tissue extracts and discriminant factor analysis. Magn Reson Med. 1993. 29:436–440.

9. Yokota H, Guo J, Matoba M, Higashi K, Tonami H, Nagao Y. Lactate, choline, and creatine levels measured by vitro 1H-MRS as prognostic parameters in patients with non-small-cell lung cancer. J Magn Reson Imaging. 2007. 25:992–999.

10. Duarte IF, Rocha CM, Barros AS, et al. Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours? Virchows Arch. 2010. 457:715–725.

11. Rocha CM, Barros AS, Gil AM, et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res. 2010. 9:319–332.

12. Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HB. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magn Reson Imaging. 1993. 11:107–118.

13. Stanwell P, Mountford C. In vivo proton MR spectroscopy of the breast. Radiographics. 2007. 27:Suppl 1. S253–S266.

14. Qayyum A. MR spectroscopy of the liver: principles and clinical applications. Radiographics. 2009. 29:1653–1664.

15. Opstad KS, Wright AJ, Bell BA, Griffiths JR, Howe FA. Correlations between in vivo (1)H MRS and ex vivo (1)H HRMAS metabolite measurements in adult human gliomas. J Magn Reson Imaging. 2010. 31:289–297.

16. Seppenwoolde Y, Shirato H, Kitamura K, et al. Precise and realtime measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys. 2002. 53:822–834.

17. Guo J, Higashi K, Yokota H, et al. In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma. J Nucl Med. 2004. 45:1334–1339.

18. Smith JK, Kwock L, Castillo M. Effects of contrast material on single-volume proton MR spectroscopy. AJNR Am J Neuroradiol. 2000. 21:1084–1089.

19. Dydak U, Schar M. MR spectroscopy and spectroscopic imaging: comparing 3.0 T versus 1.5 T. Neuroimaging Clin N Am. 2006. 16:269–283.

20. Gabr RE, Sathyanarayana S, Schar M, Weiss RG, Bottomley PA. On restoring motion-induced signal loss in single-voxel magnetic resonance spectra. Magn Reson Med. 2006. 56:754–760.

21. Weiss E, Wijesooriya K, Dill SV, Keall PJ. Tumor and normal tissue motion in the thorax during respiration: analysis of volumetric and positional variations using 4D CT. Int J Radiat Oncol Biol Phys. 2007. 67:296–307.

22. Chen W, Zu Y, Huang Q, et al. Study on metabonomic characteristics of human lung cancer using high resolution magic-angle spinning 1H NMR spectroscopy and multivariate data analysis. Magn Reson Med. 2011. 66:1531–1540.

23. Kuo YT, Li CW, Chen CY, Jao J, Wu DK, Liu GC. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging. 2004. 19:598–604.

24. Gold GE, Pauly JM, Leung AN, et al. Short echo time MR spectroscopic imaging of the lung parenchyma. J Magn Reson Imaging. 2002. 15:679–684.